EMY says a newer group of obesity drugs is beating Ozempic, though the drugs and data behind the claim aren't named here.
Recap by typeshit. Full story at emy.
A comment-for-link Instagram post saying trials of semaglutide, tirzepatide and retatrutide showed up to 28% weight loss. Little detail beyond that.
Real-world records shown at EASD 2026 had 24.1% of tirzepatide users losing 15% or more in a year, versus about 9% on semaglutide, GlobalData reports.
Survey data on 3,615 US adults showed about 30% lower odds of GLP-1 use among cancer survivors, despite more heart and kidney disease. Causes remain unclear.
11:38
RMZ digs into why weight loss results on tirzepatide vary so widely, with some people losing double what others do.
A creator covers how peptides work, how they show up in hair care, and whether they are safe to use. No study or source is cited for the hair claims.
EMY says a newer class of weight loss drugs is beating Ozempic. The drugs and the data behind the claim are not named, so tap through for the details.
Loading…